IXICO Plc (LON:IXI) has picked a new contract for its analysis technology from a US biopharma for a phase II trial of a new treatment for Huntington’s disease.
The contract value is £1.2mln over a three year term.
READ: IXICO signs extension to its largest existing contract for an Alzheimer's disease clinical trial
Giulio Cerroni, IXICO’s chief executive, said it was the first contract with this particular customer and highlights growing momentum for its services.
"We are delighted to continue our successful track record in Huntington's disease clinical studies, providing compliant data standardisation, collection and analysis to support regulatory submissions.”
READ: IXICO expands Assessa PML platform pilot to include pharmacovigilance
IXICO will use its TrialTracker digital platform to standardise the acquisition and collection of both MRI and PET scans acquired at specialist imaging centres across North America.
The images will then be analysed for patient eligibility, monitor patient safety and quantify drug effects using its image analysis workflows and algorithms.